Skip to main content
Premium Trial:

Request an Annual Quote

Ambry Genetics, Invicro Partner to Combine Imaging, Genomics Services

NEW YORK (GenomeWeb) – Ambry Genetics announced today that it will partner with Invicro to provide customized genomics and imaging services for the biotechnology and pharmaceutical industry, with a specialized focus on oncology and neurodegenerative diseases.

The partnership will combine Invicro's imaging services and software with Ambry's genomics services to expedite new drug discovery and development.

Both Ambry Genetics and Invicro were acquired by Konica Minolta in 2017, and the firms continue to operate as independent subsidiaries. As part of its plan to expand into the clinical healthcare space, Konica plans to place a special emphasis on precision medicine.

Financial terms of the partnership were not disclosed.

"With Invicro's experience and extensive biopharmaceutical network, we believe our combined expertise will deliver industry-leading solutions towards the fulfillment of precision medicine," Phillip Gray, Ambry's VP of advanced genomic services, said in a statement.